Skip to main content
Global
Global Fin Swe Nor Den Ger Cze Svk Pol Hun Nld Bel (nl) Bel (fr) USA
Log in
  • Aidian – Your aid in diagnostics
  • Products
  • About us
  • News
  • Antimicrobial resistance
  • Aidian Academy
  • Customer stories
  • Events
  • For distributors / Log in
Contact us Search
Logo
Contact us
  • Point of care
  • Microbiology
  • Molecular diagnostics
  • Hygiene monitoring
  • RIA / Collagens
  • Respiratory tract infections
  • Products available in the USA
Point of care
  • QuikRead go system
  • QuikRead 101
Read more
QuikRead go
  • QuikRead go Plus Instrument
  • QuikRead go Instrument
  • QuikRead go easy CRP
  • QuikRead go CRP
  • QuikRead go CRP+Hb
  • QuikRead go wrCRP
  • QuikRead go wrCRP+Hb
  • QuikRead go HbA1c
  • QuikRead go Strep A
  • QuikRead go iFOBT
  • QuikRead go accessories
QuikRead go
Microbiology
  • Uricult
  • Uricult Vet
  • Cultura M
Read more
Molecular diagnostics
  • SIBA
Read more
SIBA licensing and partnering opportunities
Read more
Hygiene monitoring
  • Easicult
  • Hygicult
  • Clean Card PRO
Read more
NEW! A comprehensive guide to monitoring surface hygiene now published
Read more
RIA / Collagens
  • UniQ
Read more
  • Our history
  • Board and management
  • Sustainability
  • Culture
  • Careers
  • Employee stories
  • Partnering and licensing
  • UN Global Compact Commitment | Aidian
  • News
  • Product news
  • AMR
  • Events
  • Stories from customers
  • COVID-19
  • About C-reactive protein (CRP)
  • AMR interview
  • CRP and lower respiratory tract infections
  • Educational materials
  • QuikRead go CRP products
  • Spreading of antibiotic resistant bacteria
  • Useful links
  • Generally
  • Product information
  • Courses
  • Documents and materials
  • Frequently asked questions
  • Sleeping hygiene: monitoring cleanliness of pillows and bedding
Logo
Contact us Close
  • Products
    • Point of care
      • QuikRead go system
      • QuikRead 101
    • Microbiology
      • Uricult
      • Uricult Vet
      • Cultura M
    • Molecular diagnostics
      • SIBA
    • Hygiene monitoring
      • Easicult
      • Hygicult
      • Clean Card PRO
    • RIA / Collagens
      • UniQ
    • Respiratory tract infections
    • Products available in the USA
  • About us
    • Our history
    • Board and management
    • Sustainability
    • Culture
    • Careers
    • Employee stories
    • Partnering and licensing
    • UN Global Compact Commitment | Aidian
  • News
    • News
    • Product news
    • AMR
    • Events
    • Stories from customers
    • COVID-19
  • Antimicrobial resistance
    • About C-reactive protein (CRP)
    • AMR interview
    • CRP and lower respiratory tract infections
    • Educational materials
    • QuikRead go CRP products
    • Spreading of antibiotic resistant bacteria
    • Useful links
  • Aidian Academy
    • Generally
    • Product information
    • Courses
    • Documents and materials
    • Frequently asked questions
  • Customer stories
    • Sleeping hygiene: monitoring cleanliness of pillows and bedding
  • Events
  • For distributors / Log in
Popular products
QuikRead go Plus Instrument

QuikRead go Plus Instrument

QuikRead go HbA1c

QuikRead go HbA1c

SIBA

SIBA

Latest news
View all

New Study on QuikRead go easy CRP supports the use of CRP-based scoring to improve neonatal infection management in low-resource settings

May 22, 2025 | News, Product news

May 5 is World Hand Hygiene Day

May 5, 2025 | News, Product news

Meet us at EuroMedLab 2025!

April 29, 2025 | Events

  • View all
  • No results found
  • Loading...
News

New Study on QuikRead go easy CRP supports the use of CRP-based scoring to improve neonatal infection management in low-resource settings

May 22, 2025 | News, Product news

May 5 is World Hand Hygiene Day

May 5, 2025 | News, Product news

Back to all news
March 22, 2022
News,
Product news

Bladder EpiCheck® included in the EAU Clinical Guidelines

Bladder EpiCheck® is a urine marker panel used in the monitoring of non-muscle invasive bladder cancer (NMIBC) to reduce the number of unnecessary cystoscopies. This simple, non-invasive and accurate urine test is newly included in 2022 European Association of Urology (EAU) Clinical Guidelines on NMIBC. The EAU guidelines aim to provide practical recommendations on the clinical management of NMIBC, to assist physicians in making informed treatment decisions with available scientific data. The EAU guidelines state that urinary biomarker tests with high sensitivity and negative predictive values for high-grade disease, including a specific reference to Bladder EpiCheck, might be used to replace and/or postpone cystoscopies in low- and intermediate-risk NMIBC, and reduce the number of cystoscopies in this patient population.

Bladder EpiCheck demonstrated the best performance out of the guideline-recommended markers as measured by diagnostic odds ratios in the recent meta-analysis published in European Urology Oncology1. Bladder EpiCheck analyzes subtle disease-specific changes in DNA methylation markers, allowing for the detection of 91%1 of the high-risk cancers. High risk cancers2 are important to catch as they are aggressive and most likely to progress to invasive cancer if not treated immediately. Bladder EpiCheck has demonstrated a negative predictive value (NPV) of 99% for high-grade cancer, meaning that when receiving a negative Bladder EpiCheck result, there is 99% chance that no high-grade cancer is present1. Overall specificity of Bladder EpiCheck is 85%, ensuring a low rate of false positive results.

Bladder EpiCheck is an objective molecular test meaning that it does not rely on human interpretation. The result is a clear positive/negative for presence of bladder cancer, with additional numerical results between 0-100. The results are not affected by BCG treatment, hematuria or infections.

Aidian is the proud distributor of the Bladder EpiCheck test in the Nordics. More details about the test can be found from product webpages:

  • Bladder EpiCheck (Finland)
  • Bladder EpiCheck (Sweden)
  • Bladder EpiCheck (Norway)
  • Bladder EpiCheck (Denmark)

Contact us at aidian@aidian.eu for more information on Bladder EpiCheck.


References

  1. Laukhtina et al., Corrigendum to ‘‘Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis’’ [Eur Urol Oncol 2021;4:927–42], Eur Urol Oncol (2022), https://doi.org/10.1016/j.euo.2022.01.003
  2. EAU (European Association of Urology) Guidelines: Non-muscle-invasive Bladder Cancer. Available at: https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/diagnosis


Share
Facebook
Twitter
Email

Aidian Oy

Koivu-Mankkaan tie 6 B,
FI-02200 Espoo,
Finland

P.O. Box 83,
FI-02101 Espoo,
Finland

+358 10 309 3000
Company
  • About us
  • Careers
  • Contact us
  • Events
  • Product-specific inquiries
  • Sales support
  • Sales related inquiries
  • Sustainability
Products
  • Point of care
  • Microbiology
  • Molecular diagnostics
  • Hygiene monitoring
  • RIA / Collagens
  • Respiratory tract infections
Quick links
  • Aidian Academy
  • Aidian Connect
  • IFU Revision histories
Copyright © 2025 Aidian
  • Privacy Policy
  • Privacy Statements
  • Cookie Policy
  • Social Media Policy